tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Schmidt LE et al. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients. 2003 Transplantation pmid:12883193
Burroughs TE et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 2007 Transplantation pmid:17452891
Neuhaus P et al. Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. 1995 Transplantation pmid:7530868
Méndez A et al. Pharmacokinetic study of conversion from tacrolimus twice-daily to tacrolimus once-daily in stable lung transplantation. 2014 Transplantation pmid:24492423
Moss MC et al. Lithium use for bipolar disorder post renal transplant: is mood stabilization without toxicity possible? 2014 Transplantation pmid:24492429
Fridell JA et al. Steroid withdrawal for pancreas after kidney transplantation in recipients on maintenance prednisone immunosuppression. 2006 Transplantation pmid:16906038
Misra S et al. Red cell aplasia in children on tacrolimus after liver transplantation. 1998 Transplantation pmid:9500636
Narayanan M et al. Outcomes in African American kidney transplant patients receiving tacrolimus and mycophenolic acid immunosuppression. 2013 Transplantation pmid:23423268
Butani L et al. Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. 2002 Transplantation pmid:11793001
Velidedeoglu E et al. Early kidney dysfunction post liver transplantation predicts late chronic kidney disease. 2004 Transplantation pmid:15084934
Takeguchi N et al. Inhibition of the multidrug efflux pump in isolated hepatocyte couplets by immunosuppressants FK506 and cyclosporine. 1993 Transplantation pmid:7681229
Leung W et al. Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. 1999 Transplantation pmid:10385092
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Bundick RV et al. FK506 as an agonist to induce inhibition of interleukin 2 production. 1992 Transplantation pmid:1374947
Egeland EJ et al. High Tacrolimus Clearance Is a Risk Factor for Acute Rejection in the Early Phase After Renal Transplantation. 2017 Transplantation pmid:28452920
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Hsiau M et al. Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation. 2011 Transplantation pmid:21857278
Yates CJ et al. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. 2013 Transplantation pmid:23902993
Kitayama T et al. Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression. 2003 Transplantation pmid:12605126
Guo Z et al. In vivo effects of leflunomide on normal pancreatic islet and syngeneic islet graft function. 1997 Transplantation pmid:9075844
Ciancio G et al. Use of intravenous FK506 to treat acute rejection in simultaneous pancreas-kidney transplant recipients on maintenance oral FK506. 1997 Transplantation pmid:9075856
Cooper MH et al. Rapamycin but not FK506 inhibits the proliferation of mononuclear phagocytes induced by colony-stimulating factors. 1994 Transplantation pmid:7509089
Egawa H et al. Isolated alkaline phosphatemia following pediatric liver transplantation in the FK506 ERA. 1995 Transplantation pmid:7533958
Sarwal MM et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. 2001 Transplantation pmid:11468528
Camirand G et al. Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. 2001 Transplantation pmid:11468532
Yu S et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. 2006 Transplantation pmid:16421475
Macphee IA et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 Transplantation pmid:12490779
Luan FL et al. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. 2011 Transplantation pmid:21242885
McDiarmid SV et al. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients. 1993 Transplantation pmid:7685933
Ahsan N et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. 2001 Transplantation pmid:11477347
Ho ET et al. Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review. 2013 Transplantation pmid:23542469
Shapiro R et al. Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. 2008 Transplantation pmid:18431232
Porrini E et al. Prediabetes in patients receiving tacrolimus in the first year after kidney transplantation: a prospective and multicenter study. 2008 Transplantation pmid:18431233
Veroux M et al. Impact of conversion to a once daily tacrolimus-based regimen in kidney transplant recipients with gastrointestinal complications. 2012 Transplantation pmid:22298033
Charney DA et al. Plasma cell-rich acute renal allograft rejection. 1999 Transplantation pmid:10515379
Fisher NC et al. The clinical impact of nephrotoxicity in liver transplantation. 2000 Transplantation pmid:10910259
MacDonald AS Management strategies for nephrotoxicity. 2000 Transplantation pmid:10910262
Kessler L et al. Tacrolimus-associated optic neuropathy after pancreatic islet transplantation using a sirolimus/tacrolimus immunosuppressive regimen. 2006 Transplantation pmid:16495816
Moffatt SD and Metcalfe SM Comparison between tacrolimus and cyclosporine as immunosuppressive agents compatible with tolerance induction by CD4/CD8 blockade. 2000 Transplantation pmid:10836388
Randhawa PS et al. Clinical significance of renal biopsies showing concurrent acute rejection and tacrolimus-associated tubular vacuolization. 1999 Transplantation pmid:9921801
Higgins RM et al. Conversion from tacrolimus to cyclosporine in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. 2000 Transplantation pmid:10836393
Meiser BM The best dosing for initial tacrolimus application is trough level adapted! 2005 Transplantation pmid:15714162
Podesser BK et al. Comparison of low and high initial tacrolimus dosing in primary heart transplant recipients: a prospective European multicenter study. 2005 Transplantation pmid:15714171
Garton T Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1. 2002 Transplantation pmid:12352898
Miao G et al. Development of donor-specific immunoregulatory T-cells after local CTLA4Ig gene transfer to pancreatic allograft. 2004 Transplantation pmid:15257039
Ryu S and Yasunami Y The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. 1991 Transplantation pmid:1718064
Hricik DE et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2003 Transplantation pmid:14508357
Starzl TE et al. Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. 1991 Transplantation pmid:1718068
Chan L et al. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. 2010 Transplantation pmid:20517177
Hodak SP et al. QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration: a case report. 1998 Transplantation pmid:9734501